Description: Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2 for multiple genomically selected cancers; and PRT-K4 for solid tumors. Prelude Therapeutics Incorporated was founded in 2016 and is based in Wilmington, Delaware.
Home Page: www.preludetx.com
PRLD Technical Analysis
200 Powder Mill Road
Wilmington,
DE
19803
United States
Phone:
302 467 1280
Officers
| Name | Title |
|---|---|
| Dr. Krishna Vaddi D.V.M., Ph.D. | Founder, CEO & Director |
| Dr. Peggy A. Scherle Ph.D. | Chief Scientific Officer |
| Dr. Andrew P. Combs Ph.D. | Exec. VP & Head of Chemistry |
| Dr. Edna Huang M.D. | Pres & Chief Medical Officer |
| Mr. Laurent Chardonnet | Chief Financial Officer |
| Ms. Aimee Crombie Ph.D. | Sr. VP and Head of Strategic Planning & Operations |
| Dr. Madhu Pudipeddi Ph.D. | Sr. VP of Technical Operations |
| Ms. Michele Porreca M.B.A. | Chief People Officer |
| Mr. Naveen Babbar Ph.D. | Sr. VP of Translation Medicine |
| Dr. Neelesh Sharma M.D., Ph.D. | Sr. VP of Clinical Devel. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.1447 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2020-09-25 |
| Fiscal Year End: | December |
| Full Time Employees: | 120 |